Curative Biotechnology, Inc.
CUBT
$0.01
$0.000.00%
OTC PK
| 09/30/2025 | 03/31/2025 | 06/30/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -70.31% | -- | -- |
| Depreciation & Amortization | -- | -- | 48.15% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -47.63% | -- | -- |
| Operating Income | -- | -- | 47.63% | -- | -- |
| Income Before Tax | -- | -- | 42.02% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 42.02% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 42.02% | -- | -- |
| EBIT | -- | -- | 47.63% | -- | -- |
| EBITDA | -- | -- | 47.67% | -- | -- |
| EPS Basic | -- | -- | 38.37% | -- | -- |
| Normalized Basic EPS | -- | -- | 62.31% | -- | -- |
| EPS Diluted | -- | -- | 38.37% | -- | -- |
| Normalized Diluted EPS | -- | -- | 62.31% | -- | -- |
| Average Basic Shares Outstanding | -- | -- | 44.03% | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | 44.03% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |